17:11 IST
BSE
Board Meeting Outcome
Beryl Drugs Board Meeting Outcome
Beryl Drugs Limited approved items for its 33rd Annual General Meeting and a proposal to increase material related party transaction limits.
Beryl Drugs Ltd
- Share price
- ₹25.55
- Market cap
- ₹12.96 Cr
- Revenue (annual)
- ₹18.82 Cr
- Net profit (annual)
- ₹0.42 Cr
- P/E (TTM)
- 20.8×Sector 47.3×
- Promoter holding
- 27.82%+0.34% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Board Meeting Outcome 4Board Meeting Date 4Annual General Meeting 4Promoter Buying 3Financial Results 3Other Announcement 1Debt & Borrowing 1Capacity Expansion 1Annual Report 1Adverse Business Impact 1
Time
4 announcements with these filters
17:06 IST
BSE
Board Meeting Outcome
Beryl Drugs Board Meeting Outcome
Beryl Drugs Ltd's board meeting on August 11, 2026, approved the unaudited financial results for the quarter ended June 30, 2026.
15:06 IST
BSE
Board Meeting Outcome
Beryl Drugs Board Meeting Outcome
Beryl Drugs Ltd approved relocation of its registered office within Indore. The move does not affect operations but updates the company's registered address.
18:46 IST
BSE
Board Meeting Outcome
Beryl Drugs Board Meeting Outcome
Beryl Drugs Ltd approved its audited financial statements and related party transactions during its board meeting. Results for the fiscal year ended March 2026 were confirmed.